We are experiencing some difficulties with our submission forms, which we are working to resolve. If you have any issues, please contact us at dspace-lib@mit.edu.

“Inactive” ingredients in oral medications

Thumbnail Image
Download
Name

aau6753_ArticleContent_final.pdf

Description
Accepted version
Size

864.12 KB

Format

Adobe PDF

Checksum (MD5)

5f366d7c93daa7a1ade1ba08f69e22f2

Thumbnail Image
Download
Name

aau6753_SupplementalMaterial_final.pdf

Description
Accepted version
Size

315.19 KB

Format

Adobe PDF

Checksum (MD5)

895e804d27b1c0970f4b26737e15e1c8

sword-2020-06-18T17:50:59.original.xml (130 B)
Original SWORD entry document
Author(s)
Reker, Daniel
•
Blum, Steven M.
•
Steiger, Christoph Winfried Johannes
•
Anger, Kevin E.
•
Sommer, Jamie M.
•
Fanikos, John
•
Traverso, Carlo Giovanni
Date Issued
March 2019
Journal
Science Translational Medicine
Publisher
American Association for the Advancement of Science (AAAS)
Citation
Reker, Daniel et al. '"Inactive" ingredients in oral medications.' Science Translational Medicine 11, 483 (March 2019): eaau6753 © 2019 The Authors
Version
Author's final manuscript
Abstract
Oral forms of medications contain "inactive" ingredients to enhance their physical properties. Using data analytics, we characterized the abundance and complexity of inactive ingredients in approved medications. A majority of medications contain ingredients that could cause adverse reactions, underscoring the need to maximize the tolerability and safety of medications and their inactive ingredients.
MIT Department
Massachusetts Institute of Technology. Department of Mechanical Engineering
Koch Institute for Integrative Cancer Research at MIT
Terms of Use
Creative Commons Attribution-Noncommercial-Share Alike
Persistent DSpace Link
DOI of Published Version
https://doi.org/10.1126/scitranslmed.aau6753
PrivacyPermissionsAccessibilityContact us
Notify us about copyright concerns.